DNA/Gene Microarray Market Size, Trends, Shares, Insights and Forecast – 2018-2026DNA/Gene Microarray Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
The global DNA/Gene Microarray Market is estimated to account for US$ 3,018.3 Mn in terms of value in 2020 and is expected to reach US$ 7,693.0 Mn by the end of 2027. Global DNA/Gene Microarray Market: Drivers For instance, in April 2020, Indivumed GmbH, an oncology company, launched the Oncology Alliance for Individualized Medicine, an international collaborative alliance to advance personalized medicine in cancer through IndivuType, the company's multi-omics database. Global DNA/Gene Microarray Market: Opportunities Increasing investment in DNA sequencing is expected to offer lucrative growth opportunities for players in the market. For instance, in January 2020, Element Biosciences, a biotechnology startup, raised US$ 80 million to develop DNA sequencing platform. * The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology. Request a sample copy of this report: https://www.coherentmarketinsights.com/ Key Takeaways: The global DNA/gene microarray market was valued at US$ 2,640.7 Mn in 2019 and is forecast to reach a value of US$ 7,693.0 Mn by 2027 at a CAGR of 12.4% between 2020 and 2027. The market is expected to witness significant growth owing to increasing technological advancement in microarray technology, and increasing demand for genetic testing. Gene expression and SNP analysis segment held dominant position in the global DNA/gene microarray market in 2019, accounting for 25.6% share in terms of value, followed by oncology and drug development, respectively. Increasing drug development, and demand for personalized medicine is expected to support growth of the segment over the forecast period. Browse Research Report: https://www.coherentmarketinsights.com/ Global DNA/Gene Microarray Market: Key Developments Major players in the market are focused on launching new products to expand their product portfolio. For instance, in February 2020, Twist Bioscience Corporation launched the Twist Targeted Methylation Sequencing Solution to study methylation pattern changes in a wide range of research fields including cancer Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in December 2019, Oncology Pharma, Inc. signed a Letter of Intent to acquire at least a 50% stake in Diagnomics, Inc., a private CLIA certified & CAP accredited private molecular Genomics lab and provider of DNA microarrays, Next Generation Sequencing, and real-time PCR solutions Buy-Now this research report: https://www.coherentmarketinsights.com/ End
|
|